Potential of iNKT cells to combat resistance to immune checkpoint inhibitors – MiNK Therapeutics

Quoting MiNK Therapeutics on LinkedIn:

“New publication in Oncogene spotlights a compelling case study of a durable response to our investigational iNKT cell therapy, agenT-797 in PD-1 refractory gastric cancer: ‘Overcoming Resistance to Programmed Cell Death Protein 1 (PD-1) Blockade with Allogeneic Invariant Natural Killer T-Cells (iNKT)’.

Read more about this case and the potential of iNKT cells to combat resistance to immune checkpoint inhibitors.

Thank you, Benedito A. Carneiro, MD, MS, and Matthew Hadfield, DO, for your collaboration on this important work.”

Source: MiNK Therapeutics/LinkedIn